View PDF Version - RePub - Erasmus Universiteit Rotterdam

Chapter 4.3
218
Table 2: Pharmacokinetic and viral kinetic parameters for the fi rst week of treatment for the 19 patients treated with PEG-IFN monotherapy.
Pharmacokinetic parameters Viral kinetic parameters1 Patient ke ka F/Vd tmax Cmax EC50 AUC v0 decl. wk 1 c ε
(day-1 ) (day-1 ) (pg/mL) (days) (pg/mL) (pg.wk/ mL) (log10cp/mL) (log10cp/mL) (day-1 )
1 0.42 0.60 1.30 1.98 5630 5852 26415 9.30 0.20 0.97 0.49
3 0.48 2.73 1.80 0.77 12410 6485 35918 9.49 0.35 0.96 0.66
5 0.48 1.02 1.55 1.40 7940 6713 30267 10.04 -0.48 0.90 0.54
8 0.47 4.47 1.62 0.56 12430 1400 33228 9.06 0.30 0.80 0.89
9 0.55 2.93 1.86 0.70 12610 1480 32823 8.68 0.34 0.91 0.89
11 0.46 0.91 1.43 1.52 7160 3782 28890 8.69 0.53 0.77 0.65
12 0.43 1.34 1.31 1.25 7630 3969 28079 8.36 0.24 0.87 0.66
22 0.56 4.29 1.63 0.54 12020 276 28295 9.57 1.15 0.97 0.98
24 0.50 2.07 1.93 0.91 12300 2017 37259 8.65 0.71 0.55 0.86
27 0.37 2.08 0.88 1.01 6020 5881 21372 9.03 -0.28 1.43 0.50
29 0.55 1.14 2.43 1.24 12320 3717 42477 8.36 0.10 1.58 0.77
32 0.58 0.69 3.37 1.57 13500 9634 54171 10.26 0.07 1.09 0.58
39 0.39 4.43 0.65 0.60 5140 570 15541 9.30 0.69 1.05 0.90
41 0.36 1.09 0.76 1.52 4420 3844 18654 9.94 -0.07 1.09 0.54
43 0.45 1.23 1.43 1.29 8030 12684 29735 9.53 0.11 1.08 0.39
45 0.37 1.56 0.87 1.21 5540 1078 21063 9.13 0.42 1.26 0.84
50 0.58 3.34 1.83 0.64 12660 5325 31017 9.91 0.03 0.89 0.70
51 0.58 0.71 3.29 1.56 13360 5282 53428 8.85 -0.16 1.03 0.71
73 0.43 4.09 0.87 0.61 6690 3228 19105 10.03 0.17 0.87 0.67
Median 0.47 1.56 1.55 1.21 8030 3844 29735 9.30 0.20 0.97 0.67
Q 25 0.42 1.02 0.88 0.64 6020 1480 21372 8.69 0.06 0.87 0.54
Q 75 0.55 3.34 1.86 1.52 12430 5881 35918 9.91 0.39 1.09 0.86
decl. wk 1 = the decline in viral load in the fi rst week of treatment, Q = quartile
1Identical estimates for all patients (fi xed effects) were obtained for the pharmacokinetic time delay t0 (0.9 day), the infected cell loss rate δ (0.07 per day) and the
Hill coeffi cient (n=1).